Featured News 5 must-read articles
- May 29, 2020
This site will be updated regularly with information from Mayo Clinic experts.
- May 28, 2020
Carfilzomib is not superior to Bortezomib in delaying multiple myeloma progression after initial treatment
ROCHESTER, Minn. ― Carfilzomib, a proteasome inhibitor used in combination with Lenalidomide, an immune modulating drug, is not superior to Bortezomib, Lenalidomide and Dexamethasone, in the initial treatment of multiple myeloma according…